Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study

Kristina Ehrlich, Caroline Morbach, Theresa Reiter, Peter Ulrich Heuschmann, Anke Hannemann, Martin Fassnacht, Stefan Störk, Stefanie Hahner and Timo Deutschbein

Abstract

**Background:** Endogenous Cushing’s syndrome (CS) results in increased cardiovascular (CV) morbidity and mortality. So far, most studies focussed on distinct disease entities rather than the integrity of the CV system. We here describe the design of the Cardiovascular Status in Endogenous Cortisol Excess Study (CV-CORT-EX), a study aiming to comprehensively investigate the health status of patients with endogenous CS (with a particular focus on CV phenotypes, biochemical aspects, quality of life, and psychosocial status).

**Method:** A prospective non-interventional cohort study performed at a German tertiary referral centre. At the time of enrolment, patients will be categorised as: (1) newly diagnosed overt CS, (2) recurrent overt CS, (3) CS in remission, (4) presence of mild autonomous cortisol excess (MACE). The target cohorts will be \( n = 40 \) (groups 1 + 2), \( n = 80 \) (group 3), and \( n = 20 \) (group 4). Patients with overt CS at the time of enrolment will be followed for 12 months after remission (with re-evaluations after 6 and 12 months). At each visit, patients will undergo transthoracic echocardiography, cardiac magnetic resonance imaging, 24-h electrocardiogram, 24-h blood pressure measurement, and indirect evaluation of endothelial function. Furthermore, a standardised clinical investigation, an extensive biochemical workup, and a detailed assessment of quality of life and psychosocial status will be applied. Study results (e.g. cardiac morphology and function according to transthoracic echocardiography and cardiac magnetic resonance imaging; e.g. prevalence of CV risk factors) from patients with CS will be compared with matched controls without CS derived from two German population-based studies.

**Discussion:** CV-CORT-EX is designed to provide a comprehensive overview of the health status of patients with endogenous CS, mainly focussing on CV aspects, and the holistic changes following remission.

**Trial registration:** ClinicalTrials.gov (https://clinicaltrials.gov/) NCT03880513, registration date: 19 March 2019 (retrospectively registered). Protocol Date: 28 March 2014, Version 2.

**Keywords:** Cardiac magnetic resonance imaging, Cardiovascular status, Cushing’s syndrome, Echocardiography, Endogenous, Glucocorticoid excess, Hormones, Left ventricular hypertrophy, Metabolic profile, Quality of life

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Endogenous Cushing’s syndrome (CS) is a rare disease with an annual incidence of about 4 cases per 1 million inhabitants. In around 80% of cases, the pathognomonic glucocorticoid excess is due to an inappropriate secretion of adrenocorticotropic hormone (ACTH) by a pituitary adenoma, whereas ectopic and adrenal tumours (with concomitant ACTH- or cortisol-over-secretion) are responsible for 10% of cases each [1, 2].

Irrespective of the underlying aetiology, CS patients usually present with a typical clinical phenotype (including facial plethora, proximal myopathy, purple striae, and easy bruising) and suffer from various comorbidities, including relevant cardiovascular (CV) risk factors like arterial hypertension, diabetes mellitus, and dyslipidaemia [3, 4]. The latter are likely to contribute to increased CV morbidity in CS patients, as outlined by prevalences of more than 40% for myocardial hypertrophy [5, 6], up to 30% for arteriosclerosis [7–9], and up to 5% for congestive heart failure [10, 11]. Multiple studies reported an increased mortality risk even after remission of CS. Patients mainly died of CV disease, which is probably explained by their higher incidence of myocardial infarction and ischaemic stroke compared to the general population [1, 12–16].

Physical changes, associated comorbidities, and reduced life expectancy may relevantly compromise personal wellbeing. Consistently, it has repeatedly been shown that more than half of CS patients suffer from impaired quality of life (QoL) or neuropsychiatric disorders [17–19].

It is thus intuitive to speculate that only an overarching understanding of the underlying pathophysiological mechanisms will enable appropriate and person-centred treatment of endogenous CS. Former studies, however, were often restricted to single clinical aspects (e.g. CV, biochemical, or psychosocial features) or diagnostic tools (e.g. either echocardiography or cardiac magnetic resonance imaging (MRI) for the evaluation of cardiac morphology and function). A more comprehensive diagnostic approach would certainly be favourable.

This study was designed to systematically characterise the effects of endogenous CS primarily on CV morphology and function, but also on physical impairment, biochemistry, and psychosocial status. To serve this goal, an expansive arsenal of diagnostic tools will be applied. The findings should then be put into context with various clinical, biochemical, and psychosocial measures. Of note, in order to assess the potential reversibility of dysfunctionalities after remission of endogenous CS, patients with overt disease will undergo re-evaluation after 6 to 12 months (i.e., with overt CS at baseline and with CS in remission during follow-up). Besides, CS patients will be matched to controls without CS out of the general population. For this, two large population-based control groups derived from the general population in different parts of Germany will be used: Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) [20] on the one hand, and Study of Health in Pomerania (SHIP) [21] on the other.

Design and methods
Subjects
Patients with endogenous Cushing’s syndrome
Patients with endogenous CS of any aetiology (i.e. pituitary adenoma, ectopic tumour, or adrenal adenoma / hyperplasia) will be considered eligible if the inclusion and exclusion criteria (given in Table 1) are fulfilled. In contrast, patients with iatrogenic CS or adrenal carcinoma will not be enrolled, as the course of the disease is expected to result in a different clinical picture and outcome.

At study start, endogenous CS may either be overt or in remission. Care will be taken that former diagnosis of CS was made according to published guidelines [22]. Cases with adrenal disease (i.e., an adenoma or hyperplasia), inadequate response (i.e., a serum cortisol of ≥1.8 μg/dl)

Table 1 Inclusion and exclusion criteria for the CV-CORT-EX study

Inclusion criteria:
- Patients with the initial, recurrent or former diagnosis of endogenous CS of any aetiology;
  - ACTH-dependent CS (i.e. due to a pituitary adenoma or an ectopic tumour)
  - ACTH-independent CS (i.e. due to an adrenal adenoma or hyperplasia)
- Patients with MACE, defined as the combination of an adrenal mass and a pathological 1-mg-DST serum cortisol of ≥1.8 μg/dl, but no clinical evidence of overt CS
- Age ≥ 18 years
- Written informed consent

Exclusion criteria:
- Current glucocorticoid pharmacotherapy (except hydrocortisone substitution therapy, usually applied after surgery for CS) or systemic glucocorticoid pharmacotherapy for > 12 months within the previous 3 years
- Structural heart disease or chronic heart failure (NYHA > II)
- Organ disease potentially affecting cardiac function
- ECOG status > 2
- Former or ongoing malignant diseases (including adrenocortical cancer) treated with (potentially) cardiotoxic therapy
- Arterial hypertension (uncontrolled despite > 3 antihypertensive drugs)
- Pregnancy
- Incompliance suspected or demonstrated
- Chronic renal failure (MDRD < 60 ml/min)

Abbreviations: ACTH adrenocorticotropic hormone, CS Cushing’s syndrome, DST dexamethasone suppression test, ECOG Eastern Co-operative Oncology Group, MACE mild autonomous cortisol excess, MDRD modification of diet in renal disease, NYHA New York Heart Association
during the 1 mg overnight dexamethasone suppression test (1-mg-DST), and no clinical features of CS will be classified as mild autonomous cortisol excess (MACE) [23]. Study-specific investigations will be performed during regular visits at the Division of Endocrinology (University Hospital Würzburg). In case of contraindications for a diagnostic procedure (e.g. metallic implants not allowing for a cardiac MRI), patients will not undergo the particular procedure but will still be able to participate in the study. The same applies for patients who are not able or not willing to undergo certain procedures (e.g. inability to perform a chair rising test due to severe myopathy).

Control subjects
In order to elucidate the effects of endogenous CS, results from affected patients and controls without CS will be compared (e.g. evaluating their respective cardiac morphology and function, as described by transthoracic echocardiography and cardiac MRI). For this, subjects from two German population-based studies will be matched for possible contributors (mainly age, gender, and hypertension). A matching ratio of 1:2 (patients with CS to controls without CS) will be aimed for.

Prospective Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) cohort study is a population-based study of inhabitants aged 30 to 79 years from the general population of Würzburg (Germany) [20]. STAAB includes a representative cohort of 5000 men and women without previous history of heart failure at baseline. As the echocardiographic workup in STAAB and CV-CORT-EX will be identical (i.e., the same investigators will apply the same diagnostic tools according to standardised operating procedures), even subtle effects of glucocorticoid excess on echocardiographic parameters will hopefully be detected [20, 24].

The Study of Health in Pomerania-Trend (SHIP-Trend) is a population-based, longitudinal study conducted in North-East Germany [21]. It is based on a representative sample including adult men and women aged between 20 and 79 years from the study region. Baseline examinations were conducted in 4420 men and women between 2008 and 2012. This study will particularly be used to elucidate differences in the cardiac MRI of patients with endogenous CS and controls without the disease.

In addition, data from both population-based studies will also be used to compare the results from other diagnostics applied in the CV-CORT-EX study (e.g. from 24-h ECG, 24-h blood pressure monitoring, and questionnaire assessment).

Methods
Study design and study visits
The prospective CV-CORT-EX study will be conducted at a single German tertiary referral centre (University Hospital Würzburg) and is designed as an interdisciplinary collaborative project including the Divisions of Endocrinology and Cardiology, and the Comprehensive Heart Failure Centre. CV-CORT-EX combines a cross-sectional and a longitudinal phase. Screening and recruitment of eligible patients registered with an endogenous CS at the Division of Endocrinology will be performed between October 2014 and October 2023. Each patient will be actively invited to participate and will be informed by the study physician that participation is voluntary and that termination is possible at any time. The patient will also be informed about the examinations that should be performed during the study and their potential risks. All patients will be enrolled into the cross-sectional arm and undergo comprehensive phenotyping after written informed consent. Further, patients with overt CS will also qualify for the longitudinal arm. After an intervention resulting in remission of CS (usually surgical removal of the causative tumour), patients will be followed for 12 months (with re-evaluations after 6 and 12 months, i.e. with overt CS at baseline and with CS in remission during follow-up).

Participant retention and completion of study will be promoted through various aspects: a) performance of the most relevant study investigations on a single day; b) continuous support of study participants by the same study staff member(s), including organisation of ambulatory sampling procedures and organisation of transports and hospital visits; c) early communication between study participants and study staff member(s) to schedule re-visits (applying a study calendar with all relevant dates, timelines, and deadlines for each individual). Data from patients who decide to withdraw their study consent will be excluded.

Objectives
CV-CORT-EX aims to comprehensively describe CV health as well as CV related comorbidities in patients with endogenous CS. In particular, our intention is to assess the association of presence and magnitude of glucocorticoid excess to the extent of left ventricular (LV) impairment. Our present data will be compared with those obtained from a control group (matched for relevant contributors like age, sex, and hypertension). Table 2 summarises primary and secondary objectives of the study.

Evaluation of medical history and definition of CV risk factors
At each study visit, a detailed standardised medical history will be recorded, particularly focusing on CV risk factors (i.e., arterial hypertension, diabetes mellitus, dyslipidaemia, smoking), other endocrine diagnoses (e.g. hypothyroidism), and the current medication. Arterial
Table 2 Primary and secondary study objectives

Primary study objectives:
- Prevalence and magnitude of LV hypertrophy (transthoracic echocardiography)
- Description of LV deformation characteristics (transthoracic echocardiography)
- Quantification of LV, total heart mass, and ventricular volumes (cardiac MRI)
- Assessment of systolic function and myocardial structural fibrosis (cardiac MRI)

Secondary study objectives:
- Cardiac morphology and function (using transthoracic echocardiography and cardiac MRI)
- Endothelial function (using Endo-PAT2000)
- Blood pressure (using resting and 24-h blood pressure measurement)
- Heart rate variability profile (using resting and 24-h electrocardiogram)
- Clinical features (waist-to-hip ratio, body mass index, bio-impedance analysis)
- Muscle strength (chair rising test, hand grip strength)
- Biochemistry (including hormonal, metabolic, cardiac and routine parameters)
- Evaluation of QoL and psychosocial status (using six questionnaires):
  - Disease-specific QoL (CushingQol, Tuebingen CD-25)
  - Generic QoL (SF-36)
  - Generic health status (EQ-5D-3L)
  - Anxiety (GAD-7)
  - Depressive and panic disorders (brief PHQ-D)
- Comparison between patients with CS and controls without CS (i.e. from STAAB and SHIP-Trend)
- Comparison between patients with overt CS and patients with CS in remission

Abbreviations: CS Cushing’s syndrome, LV left ventricular; MRI magnetic resonance imaging, QoL quality of life, SHIP-Trend Study of Health in Pomerania-Trend, STAAB Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression

hypothesis, diabetes mellitus, and dyslipidaemia will be assumed in case of specific pharmacotherapy or pathological results during the visit. Smoking status (i.e., current, former, or non-smoking) will also be recorded. In case of current or former smoking, the number of pack-years will be calculated (20 cigarettes = one pack; one pack per day for one year = one pack year).

Evaluation of clinical features
Patients will undergo a comprehensive physical examination by an experienced endocrinologist, including assessment of possible CS stigmata (e.g. facial plethora, purple striae, or hirsutism).

Patients’ height and weight will be measured with a Seca 200 scale with an integrated measuring rod (Seca, Hamburg, Germany). Body mass index (BMI) will be calculated, dividing body weight by the square of height in metres (kg/m²).

After a five-minute rest in sitting position, resting blood pressure and heart rate will be measured in triplicate with a BoSo Medicus Prestige blood pressure cuff (BoSo Medicus, Jungingen, Germany) and a 3 M Littmann Classic III stethoscope (3 M, Neuss, Germany). Subsequently, the respective means will be calculated.

A conventional 12-lead ECG will be recorded in recumbent position, using the GE KISS device (GE Healthcare, Munich, Germany).

The circumference of three body sites will be determined with a Seca 206 stretch-resistant tape (Seca, Hamburg, Germany). Patients will have to remain in standing position (with slightly raised arms) and breathe normally during the measurement procedure. Three measurements will be performed: 1) dominant upper arm (between the acromion and olecranon); 2) waist circumference (at the midpoint between the lower margin of the last palpable ribs and the top of the iliac crest); 3) hip (at the level of the widest portion of the buttocks). Subsequently, the waist-to-hip ratio (WHR) will be calculated [25].

Bio-impedance analysis (BIA) will be performed to quantify the proportion of muscle, fat, and water. For this, the patient has to remain in horizontal position for 10 min before starting the test. Two pairs of electrodes will be fixed on the dorsal side of the hand and foot of the dominant side and will then be connected to the impedance analyser BIA 2000-S (Data Input, Wedemark, Germany). Subsequently, resistance, reactance, and phase angle will be measured via computer software, thereby determining body composition (using weight, height, age and sex as additional parameters for the distinct calculations).

With respect to the longitudinal sub-study, facial photographs (frontal and profile view) will be taken from each patient to examine the development of typical CS stigmata over time.

Evaluation of muscle strength
The possibility of myopathy will be indirectly evaluated by measurement of hand grip strength. Patients will grasp a hydraulic Jamar handgrip dynamometer (Patterson Medical, Warrenville, IL, USA) with the arm right-angled and at maximum force. The arithmetic mean of three readings will be calculated for each hand. Limbs with known muscle dysfunction (e.g. due to a former stroke) will be excluded from the analysis.

In addition, each patient will undergo a chair rising test as described elsewhere [26]. In short, patients are asked to rise from a sitting position at a chair of 45 cm height until full knee and hip extension. The arms must be kept crossed over the chests while performing the
chair rising test. Five repetitions at maximum speed should be performed starting in sitting and ending in standing position. The read-out is the time needed to execute the task, with longer durations corresponding to more severe muscle weakness and a higher risk of falls [26].

**Evaluation of biochemical parameters**

After an overnight fast of at least 8 h, participants will undergo blood sampling between 8:00 and 9:00 a.m. These samples will be used for a comprehensive biochemical evaluation (including hormonal, metabolic, cardiac, and various routine parameters). An overview of the standardised biochemical profile is provided in Table 3. All measurements will be performed at the University Hospital Würzburg.

Presence and remission of CS will be confirmed via evaluation of serum cortisol during the 1-mg-DST, diurnal salivary cortisol profiles (with saliva sampling at five time points throughout a day: 08.00 a.m., 12.00 a.m., 4.00 p.m., 8.00 p.m., and 11.00 p.m.), and 24-h urinary free cortisol (taking into account published criteria, e.g. [22]). Additional biosamples (i.e. urine, blood, saliva) for medical research purposes will also be collected and stored at a local biobank (Interdisciplinary Bank of Biomaterials and Data Würzburg, ibdw) [27]. For this, samples will be transferred to the ibdw within 30 min after their collection before being pseudonymised, centrifuged, aliquoted, and stored at −80 °C (all steps will be performed according to standardised operating procedures).

**Evaluation of quality of life and psychosocial status**

To evaluate quality of life and psychosocial status, a total of six questionnaires will be handed out to the participants in printed form. Both the CushingQoL and the Tuebingen CD-25 are disease-specific questionnaires for patients with endogenous CS [28, 29]. While the CushingQoL was established for patients with endogenous CS (irrespective of the underlying aetiology), the Tuebingen CD-25 was specifically developed for patients with Cushing’s disease. Generic health status, generic QoL, anxiety, and depressive and panic disorders will be evaluated by the questionnaires EuroQoL-5D-3L (EQ-5D-3L), Short Form 36 (SF-36), Generalized Anxiety Disorder 7 (GAD-7), and brief Patient Health Questionnaire (brief PHQ-D) [30–33].

**Transthoracic echocardiography**

Detailed transthoracic echocardiography will be performed and analysed by well trained personnel, using an ultrasound machine (Vivid 9 and Vivid E95, GE, Horton, Norway) with a 3.5 MHz sector scanner according to the standardised protocol of the Comprehensive Heart Failure Centre Würzburg. Subsequently, each investigation will be reviewed blinded to the previous results. Measurements will include standard variables of myocardial morphology and function as well as more advanced readings like speckle-tracking derived strain imaging and the assessment of myocardial work.

**Cardiac magnetic resonance imaging**

Cardiac MRI scans will always be acquired on clinical 1.5 T and 3.0 T scanners (Achieva (1.5 T) and Achieva DS (3.0 T), Philips Healthcare, Best, The Netherlands). Gadobutrol (Dosage 0.15 mmol/kg, Bayer, Leverkusen, Germany) will be used as contrast agent. According to recommendations published by the Society for Cardiovascular Magnetic Resonance (SCMR), the local protocol contains CINE imaging in short and long axes, flow measurements in the aorta ascendens and main pulmonary artery, and detection of global and focal fibrosis with late enhancement imaging and parametric mapping.

**Table 3** Main parameters of the standardised biochemical profile

| Endocrinology                          | Metabolism                  | Cardiology                  | Routine laboratory                |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------------|
| Diurnal salivary cortisol profile       | Fasting glucose             | Creatine kinase             | Haematology (differential blood count) |
| Serum cortisol during the 1-mg-DST      | Hba1c                       | CK-MB                       | Electrolytes (sodium, potassium, magnesium, calcium, chloride, phosphate) |
| 24-h urinary free cortisol             | Triglycerides               | High-sensitive troponin T   | Liver parameters (GOT, GPT, y-GT, alkaline phosphatase, bilirubin) |
| Hair cortisol                          | Cholesterol (total, LDL, HDL) | NTproBNP                   | Kidney parameters (creatinine, urea, GFR) |
| Basal serum cortisol                   | Metabolomics                |                             | hsCRP                             |
| Basal ACTH                             |                             |                             | Coagulation (Quick, INR, PTT)     |

**Abbreviations:** ACTH, adrenocorticotropic hormone; CK-MB, creatine kinase muscle-brain type; DST, dexamethasone suppression test; GFR, glomerular filtration rate; GOT, aspartate aminotransferase; GPT, alanine aminotransferase; HDL, high-density lipoprotein; hsCRP, high-sensitive C-reactive protein; INR, international normalised ratio; LDL, low-density lipoprotein; NTproBNP, N-terminal prohormone of brain natriuretic peptide; PTT, partial thromboplastin time; y-GT, gamma-glutamyltransferase.
Standard clinical parameters will be analysed according to the recommendations of the SCMR and all data will be stored as Digital Imaging and Communications in Medicine (DICOM) format for further post-processing [34]. The interpretation of the cardiac MRI scans will be performed by a cardiac MRI certified cardiologist and separately reviewed by a blinded experienced cardiologist with special training in cardiac MRI. Discrepant results will be decided in consensus or through involvement of a third investigator.

24-h electrocardiogram and blood pressure measurement
All study participants will undergo 24-h analyses of heart rate and blood pressure. Heart rate will be recorded using the Philips Digi Trak XT (Philips, Hamburg, Germany). Scans will be evaluated by experienced cardiologists, and mean heart rate during day and night time as well as heart rate variability will be derived (i.e. a 24-h ECG). Blood pressure will be recorded using a Custos screen 300 (custo med, Ottobrunn, Germany) blood pressure cuff applied to the left upper arm. Blood pressure measurements will be taken every 15 min (between 6.00 a.m. and 10.00 p.m.) or every 30 min (between 10.00 p.m. and 6.00 a.m.). Mean blood pressure during day and night time and dipping status will be evaluated.

Evaluation of endothelial function
The Endo-PAT2000 device (Itamar medical, Israel) offers non-invasive evaluation of endothelial function and will be used according to the manufacturer’s instructions. A blood pressure cuff will be attached to the non-dominant arm and probes to each index finger. After a preparatory phase of 6 minutes, the arterial blood flow into the arm will be interrupted via the blood pressure cuff. After 5 minutes of hypoxemia the blood pressure cuff will be removed to re-establish blood circulation. Vasodilatation will be assessed via measurement of increasing pulse wave deflection (peripheral arterial tone, PAT) via an integrated plethysmograph. Endothelial function will be assessed via the reactive hyperaemia index defined as ratio of the post-to-pre occlusion PAT amplitude of the occluded side, divided by the post-to-pre occlusion ratio of the control side. Arterial stiffness will be evaluated via the augmentation index quantified via pulse waveform analysis of the PAT signal and normalised to a heart rate of 75 bpm.

Data collection and management
Source data are the electronically generated original results of technical examinations, including biochemical analyses. The responsible study team (including physicians and nurses) will enter all collected data into case report forms (CRFs). Missing investigations or data in the CRFs will be flagged, along with a statement on the specific reason. Corrections will be made in accordance with Good Clinical Practice (GCP) guidelines, i.e. the version to be corrected will be crossed out so that it is still legible. The corrections (or other entries) will be marked with the date, hand sign and, if necessary, the reason for the changes conducted by the investigator. Incorrect entries will not be covered with correction fluid, erased, or otherwise rendered illegible. Finally, all data will be transferred into an excel file by the responsible study team. The investigator will maintain a patient identification list which will enable the unique assignment of patient numbers to patient name, date of birth, and sex.

Sample size
Due to the rarity of the disease and the paucity of literature, reliable data on cardiac morphology and function in patients with endogenous CS are lacking. Accordingly, this is an explorative study only (i.e. without formal calculation of case numbers), and the collected data will be used for a post-hoc power analysis. The estimated number of participants is $n = 140$ patients. The target cohorts will be $n = 40$ (for patients with newly diagnosed or recurrent overt CS), $n = 80$ (for patients with CS in remission), and $n = 20$ (for patients with MACE).

Statistical considerations
Results will be interpreted on the basis of a complete-case analysis. Missing data or investigations that cannot be interpreted will be excluded. Distribution of data will be evaluated by the Shapiro-Wilk test and quantile-quantile plots, as appropriate. Data will be reported by mean (SD), median (quartiles), and count (percent), as appropriate. $X^2$-test, Mann-Whitney U-test or Kruskal-Wallis test will serve to compare groups. Changes from baseline to follow-up will be assessed using Wilcoxon’s signed-rank test. Univariable associations will be analysed with the Spearman’s rho coefficient. ANCOVA models and multivariable linear regression models will be applied to examine the impact of cofactors or potential confounders on crude or change variables.

Discussion
Endogenous CS is associated with various CV risk factors leading to increased CV morbidity and mortality [2]. So far, studies reporting on CV outcome in patients with endogenous CS primarily focused on particular pathogenic aspects, applied single diagnostic tools, and had a cross-sectional rather than a longitudinal approach. The CV-CORT-EX study aims for a comprehensive CV, biochemical, and psychosocial workup of a representative number of cases with endogenous CS.

Arterial hypertension is quantitatively the most important modifiable risk factor for premature CV disease [35, 36]. It is present in up to 85% of patients with CS, and these numbers are independent of the underlying
CS subtype [36]. As endogenous CS is also associated with other relevant risk factors for the development of atherosclerosis (e.g. diabetes mellitus, dyslipidaemia, chronic inflammation, endothelial dysfunction) [4, 35, 37–39], it is no surprise that an increased intima media thickness of the common carotid (as an indicator of atherosclerotic damage) has already been described in such cohorts [7, 9]. Accordingly, non-selected screening for atherosclerosis appears reasonable in case of endogenous CS. Ultrasound (e.g. of the common carotid) is observer-dependent and rather time-consuming. The fact that endothelial dysfunction is known as an early indicator of cardiovascular disease is the rationale for the use of Endo-PAT2000 device in the CV-CORT-EX study. Of note, progression of atherosclerotic plaques over time (with the consequence of slow luminal narrowing) may affect not only peripheral, but also coronary and cerebral arteries [37, 40]. Consequently, if multidetector computerised tomographic coronary angiography was applied to a cohort of CS patients, significantly more (non-) calcified coronary plaques than in a control group were observed [41].

Previous echocardiographic studies already described systolic and diastolic dysfunction as well as structural changes of the heart (particularly LV hypertrophy) in patients with endogenous CS [42–45]. Myocardial fibrosis, and reduced systolic and diastolic performance were more frequent in CS than in hypertensive controls (matched for LV hypertrophy) and healthy subjects [46]. Of note, at least two studies clearly illustrate the benefits of cardiac MRI to detect potential cardiac pathologies that are not discovered by common echocardiography [47, 48]. As a result, our aim for a combined diagnostic integration of myocardial and valvular functional status (as assessed by echocardiography) and information on cardiac morphology and myocardial fibrosis (as assessed by cardiac MRI) appears reasonable.

After remission of CS, several studies reported a reduced frequency of hypertension [9, 14, 49] on the one hand, and LV hypertrophy as well as diastolic dysfunction on the other [44, 45, 47, 48]. The same was true for CV risk factors [8, 9] and regression of myocardial fibrosis [46]. Nevertheless, the prevalence of these alterations were usually still higher compared to healthy controls [43, 45]. Besides, an increased prevalence of coronary arterial disease despite long-term remission was particularly noted for women and younger patients [50].

Although much less frequent than other CV impairments, pathological ECG findings (e.g. arrhythmias) have also been attributed to endogenous CS. In detail, irregular sinus rhythm, inverted T waves, signs of biventricular (particularly left) hypertrophy, prolonged QT, and a higher risk of impaired heart rate variability were reported, suggesting a cardiotoxic effect of excessively elevated glucocorticoids per se [36, 51–53]. Proximal myopathy is a relevant clinical finding that is present in about 40–80% of patients with overt CS [13, 54, 55]. Interestingly, while some reported a higher prevalence of myopathy in males [56], others did not find any sex-related differences [54, 55].

A higher risk of psychiatric illness (e.g. depression, anxiety, cognitive dysfunction) and a pronounced impairment of QoL have also been observed during overt CS [17–19, 57, 58]. Obviously, this is not only due to incriminatory phenotypical changes and various comorbidities, but also to effects of glucocorticoids itself [59–62]. Interestingly, female sex [28, 63, 64] and hypopituitarism [63] were described as predictors of impaired QoL. Despite remission of CS and adequate therapy of psychiatric comorbidity, persisting or sometimes even deteriorating neuropsychiatric disorders and QoL have been described [58–60, 65]. Of note, some studies even described suicidal tendencies or suicides in (currently or formerly) affected CS patients [17, 57]. Taken together, a broad assessment of quality of life and psychiatric affection appears worthwhile.

In summary, adequate treatment (both of the glucocorticoid excess and of its associated comorbidities) and continuous interdisciplinary support are required for a satisfactory long-term outcome of patients with endogenous CS. In the long-term, the CV-CORT-EX trial will hopefully pave the way for improved medical care in the future.

Abbreviations
ACTH: Adrenocorticotropic hormone; BIA: Bio-impedance analysis; Brief PHQ-D: Brief Patient Health Questionnaire; CK-MB: Creatine kinase muscle-brain type; CS: Cushing’s syndrome; CV: Cardiovascular; CV-CORT-EX: Cardiovascular Status in Endogenous Cortisol Excess Study; DICOM: Digital Imaging and Communications in Medicine; DST: Dexamethasone suppression test; ECOG: Eastern Co-operative Oncology Group; ECG: Electrocardiography; EQ-SD-3L: EuroQol-5D-3L; GCP: Good Clinical Practice; GAD-7: Generalized Anxiety Disorder 7; GFR: Glomerular filtration rate; GGT: Glutamyltransferase; HDL: High-density lipoprotein; hsCRP: High-sensitive c-reactive protein; ibdw: Interdisciplinary Bank of Biomaterials and Data Würzburg; INR: International normalised ratio; LDL: Low-density lipoprotein; LV: Left ventricular; MACE: Mild autonomous cortisol excess; MDRD: Modification of diet in renal disease; MRI: Magnetic resonance imaging; NTproBNP: N-terminal prohormone of brain natriuretic peptide; NYHA: New York Heart Association; PAT: Peripheral arterial tone; PTT: Partial thromboplastin time; QoL: Quality of life; STAAB: Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression; SCMR: Society for Cardiovascular Magnetic Resonance; SHIP: Study of Health in Pomerania; SF-36: Short Form 36; WHR: Waist-to-hip ratio; y-GT: Gamma-glutamyltransferase

Acknowledgements
We would like to thank the teams from the participating institutions for their commitment to the study.

Authors’ contributions
TD, SS, MF, and SH developed the study outline and were in charge of funding acquisition and methodology. CM and TR wrote the standard operating procedures and established the diagnostic workflow for transthoracic echocardiography and cardiac magnetic resonance imaging. PUH and AH as representatives of the STAAB and SHIP consortia designed the methodology for the comparative analysis of the three study cohorts (CV-CORT-EX, STAAB, and SHIP). KE and TD prepared the first draft of the manuscript. All authors contributed to the preparation of the study protocol.
and are in charge of resources, visualization, validation, and data curation. TD is the supervisor of the CV-CORT-EX study, SH is the administrator. Investigations will primarily be performed by KE, TD, SH, and MF (clinical examination), CM (transesophageal echocardiography), and TR (cardiac magnetic resonance imaging). KE and TD will conduct the primary statistical analysis (along with SS, PUH, and AH). As for the protocol, study authorship will follow International Committee of Medical Journal Editors recommendations current at the time of manuscript preparation. We do not intend to use professional writers. The author(s) read and approved the final manuscript.

**Funding**

Timo Deutschbein (grant number Z-2/57) and Theresa Reiter (grant number ZZ-23) received personal grants from the Interdisciplinary Center for Clinical Research (IZKF) of the University of Würzburg (https://www.med.uni-wuerzburg.de/izkf/startseite). The CV-CORT-EX study is supported by the Comprehensive Heart Failure Center (https://www.ukw.de/ behandlungscentren/dzhi/startseite). The BMBF grant numbers are #01EO1004 and #01EO1504. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Study data will only be accessible by study team members directly involved in study conduction and analysis.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of the University Hospital Würzburg (245/14) and was subsequently registered at ClinicalTrials.gov (NCT number: NCT03880513). The study will be performed according to the International Conference on Harmonisation GCP Guidelines and the Declaration of Helsinki. All study participants will have to provide written informed consent before enrolment.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that no competing interests exist.

**Author details**

1Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Oberdörnbacher Straße 6, 97080 Würzburg, Germany. 2Department of Internal Medicine I, Division of Cardiology, University Hospital Würzburg, University of Würzburg, Würzburg, Germany. 3Comprehensive Heart Failure Centre, University and University Hospital Würzburg, University of Würzburg, Würzburg, Germany. 4Academic Core Lab Ultrasound-based Cardiovascular Imaging, University Hospital Würzburg, University of Würzburg, Würzburg, Germany. 5Clinical Trial Centre, University Hospital Würzburg, University of Würzburg, Würzburg, Germany. 6Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany. 7Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. 8German Centre for Cardiovascular Research DZHK, Partner Site Greifswald, University Medicine Greifswald, Greifswald, Germany. 9Medicover Oldenburg MVZ, Oldenburg, Germany.

Received: 19 November 2020 Accepted: 11 December 2020

**Published online:** 08 January 2021

**References**

1. Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjere P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117–23.
2. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386:913–23.
3. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Obes Res. 1994;2:486–508.
4. Nieman LK. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173:33–8.
5. Sugihara N, Shimizu M, Shimizu K, Ito H, Miyamoto I, Nakabayashi H, et al. Disproportionate hypertrophy of the interventricular septum and its regression in Cushing’s syndrome. Report of three cases. Intern Med. 1992;31:407–13.
6. Baykan M, Erem C, Gedikli O, Hachasanoglu A, Erdogan T, Kocak M, et al. Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing’s syndrome. Echocardiography. 2008;25:182–90.
7. Albiger N, Testa RM, Almoot B, Ferrari M, Bilosa F, Petrelli F, et al. Patients with Cushing’s syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res. 2006;38:405–10.
8. Colao A, Pirvov R, Spezia AF, Ferone D, Filippella M, Marullo P, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664–72.
9. Faggiano A, Pirvov R, Spezia S, de Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88:2527–33.
10. Youngre PA, Shmidt D, Wiles PG. Cushing’s syndrome: still a potential killing disease. J R Soc Med. 1995;88:174–5.
11. Mancini T, Kola B, Mantero F, Bocaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol. 2004;61:768–77.
12. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JHC, et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:78–81.
13. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Congalen JV, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol. 2011;75:436–42.
14. Hassan-Smith ZK, Sherlock M, Reulen RC, Arth W, Ayuk J, Toogood AA, et al. Outcome of Cushing’s disease following transphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 2012;97:1194–201.
15. Enahre J, Vazquez J. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol. 1994;40:749–84.
16. Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntai G, et al. Mortality in patients with Cushing’s disease more than 10 years after a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 2016;4:569–76.
17. Haskell RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry. 1985;142:911–6.
18. Kelly WF. Psychiatric aspects of Cushing’s syndrome. QJM. 1996;89:543–51.
19. Starkman M. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin N Am. 2013;42:477–88.
20. Wagner M, Tiffe T, Morbach C, Gelbrich G, Stork S, Heuschmann PU. Characteristics and course of heart failure stages A-B and determinants of progression - design and rationale of the STAAB cohort study. Eur J Prev Cardiol. 2017;24:468–79.
21. Völkze H, Alte D, Schmidt CC, Rodke D, Lorbeer B, Friedrich N, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40:4294–307.
22. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.
23. Elhassan YS, Alahdab F, Piette A, Delkavanis DA, Khanna A, Prokop L, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171:107–16.
24. Morbach C, Gelbrich G, Breunig M, Tiffe T, Wagner M, Heuschmann PU, et al. Impact of acquisition and interpretation on total inter-observer variability in echocardiography: results from the quality assurance program of the STAAAB cohort study. Int J Card Imaging. 2018;34:1057–65.
25. Pischon T, Boehing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20.
26. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:83–95.
27. Geiger J, Kircher S, Neumann M, Rosenwald A, Jahns R. Hospitalized patients with atrial fibrillation and left ventricular systolic dysfunction: who benefits from starting a beta blocker? J Interven Cardiol. 2013;26:315–21.
28. Ehrlich et al. BMC Endocrine Disorders (2021) 21:11

**Page 8 of 9**
28. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol. 2008;158:623–30.
29. Millan M, Teufel P, Honegger J, Gallwitz B, Schnaider G, Paans T. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin Endocrinol. 2012;76:851–60.
30. Spitzer RL, Kroenke K, Williams JBW, Loewee B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1004–7.
31. Rabin R, Chiar F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2009;33:337–43.
32. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Handanweisung, 1st ed. Göttingen: Hogrefe; 1998.
33. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282:1737–44.
34. Schulz-Menger J, Bluemcke DA, Bremench J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15:35.
35. Wilson PW. Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens. 1994;7:7–12.
36. Isidori AM, Grazio C, Paragiola RM, Cozzolino A, Ambrogio AG, Colao A, et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2011;29:44–60.
37. Fruchart JC, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109:15–9.
38. Arnoldi A, Angela J, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:593–602.
39. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167:311–26.
40. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410–22.
41. Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, et al. The hypertension of Cushing’s syndrome: role of endogenous hypercortisolism. Neuroendocrinology. 2013;97:309–17.
42. Alexander K, Kalsas GA, Voulotis AI, Papapapasou TG, Tiskl L, Zios A, et al. Specific electrocardiographic features associated with Cushing’s disease. Clin Endocrinol. 2011;74:558–64.
43. Hey TM, Dahl JS, Brix TH, Søndergaard EV. Biventricular hypertrophy and heart failure as initial presentation of Cushing’s disease. BMJ Case Rep. 2013;2013:bcr201301307.
44. Berr CM, Stieg MR, Deutschbrien T, Quinkler M, Schmidmaier R, Osowald A, et al. Persistence of myopathy in Cushing’s syndrome: evaluation of the German Cushing’s Registry. Eur J Endocrinol. 2017;176:337–46.
45. Vogel F, Braun LT, Rubinstein G, Zopp S, Künzel H, Strading F, et al. Persisting muscle dysfunction in cushing’s syndrome despite biochemical remission. J Clin Endocrinol Metab. 2020;105(12):e4490–e4498. https://doi.org/10.1210/clinem/dgaa265.
46. Pecori Giraldi F, Moro M, Cavagnini F. Gender-related differences in the presentation and course of Cushing’s disease. J Clin Endocrinol Metab. 2003;88:1554–8.
47. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction of H hypercortisolism. J Clin Endocrinol Metab. 1997;82:917–22.
48. Santos A, Crespo I, Aulinis A, Resmini E, Valassi E, Webb SM. Quality of life in Cushing’s syndrome. Pituitary. 2015;18:195–200.
49. Webb SM, Santos A, Resmini E, Martinez-Momblan MA, Martel L, Valassi E. Quality of life in Cushing’s disease: a long term issue? Ann Endocrinol. 2018;79:131–7.
50. Pironello R, Simeoli C, de Martinco MC, Cozzolino A, de Leo M, Laccianelli D, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci. 2015;9:129.
51. Patil CG, Shivanand PL, Katzenlgl L, Laws ER. Brain atrophy and cognitive deficits in Cushing’s disease. Neurosurg Focus. 2007;23:E11.
52. De Kloet ER, Wreegdendh E, Otal MS, Jolts M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269–81.
53. van Aken MO, Pereira M, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, et al. Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab. 2005;90:3279–86.
54. Wagenmakers MAEM, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus ARMM. Impaired quality of life in patients after long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur J Endocrinol. 2012;167:687–95.
55. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman MK. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91:447–53.